Journal
JOURNAL OF APPLIED MICROBIOLOGY
Volume 112, Issue 1, Pages 138-146Publisher
WILEY
DOI: 10.1111/j.1365-2672.2011.05186.x
Keywords
antifungal drugs; Bombyx mori; Cryptococcus neoformans; novel infection model; quantitative evaluation
Categories
Funding
- National Institute of Biomedical Innovation (NIBIO)
- Ministry of Health, Labour and Welfare (Research on Biological Resources and Animal Models for Drug Development)
- Genome Pharmaceuticals Institute Co., Ltd (Tokyo, Japan)
- Medical Mycology Research Center, Chiba University [10-25, 11-1]
- [21790062]
- Grants-in-Aid for Scientific Research [23249009, 24790069] Funding Source: KAKEN
Ask authors/readers for more resources
Aims: To develop an in vivo system that could quantitatively evaluate the therapeutic effects of antifungal drugs using a silkworm infection model with Cryptococcus neoformans. Methods and Results: Silkworms reared at 37 degrees C died after an injection of viable serotype A C. neoformans fungus into the haemolymph. The serotype A C. neoformans, which is known to have higher mammal pathogenicity than the serotype D, was also more virulent against the silkworm. Furthermore, the deletion mutants of genes gpa1, pka1 and cna1, which are genes known to be necessary for the pathogenesis in mammals, showed an increase in the number of fungal cells necessary to kill half of the silkworm population (LD50 value). Antifungal drugs, amphotericin B, flucytosine, fluconazole and ketoconazole, showed therapeutic effects in silkworms infected with C. neoformans. However, amphotericin B was not therapeutically effective when injected into the silkworm intestine, comparable to the fact that amphotericin B is not absorbed by the intestine in mammals. Conclusions: The silkworm-C. neoformans infection model is useful for evaluating the therapeutic effects of antifungal drugs. Significance and Impact of the Study: The silkworm infection model has various advantages for screening antifungal drug candidates. We can also elucidate the cryptococcal pathogenesis and evaluate the in vivo pharmacokinetics and toxicity of each drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available